COSHINGNCT03974789
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
StatusActive, Not Recruiting
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 7 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Study completion pushed from Jul 2026 to Jul 1, 2027
- Secondary endpoints: details revised at 6 of 6 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Jul 2025 to Jul 1, 2025
- Study completion date: Jul 2025 to Jul 2026
- Site details revised
- Notable Primary and study completion dates: Jul 2023 to Jul 2025
- Site contact updated
- Notable Primary and study completion dates: Jul 2021 to Jul 2023v5
- Notable Eligibility criteria expanded, about 24 wordsv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Jun 2021 to Jul 2021
- Start date changed from estimate of Jun 2019 to Jul 1, 2019
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Salivary cortisol measured by Roche Elecsys cortisol kit
Timeframe: Day 1 (at screening)
Salivary cortisol measured by IDS cortisol dosing kit at screening
Timeframe: Day 1 (at screening)
Secondary (6)
Salivary cortisol measured by Roche Elecsys cortisol kit
Salivary cortisol measured by IDS cortisol dosing kit
Salivary cortisol measured measured by LC-MS/MS
Dexamethasone suppression test
Diurnal variation of plasma cortisol
Show 1 moreShow less
Urinary free cortisol
Arms and interventions
Suspected Cushing Disease
Diagnostic tests: Blood test, 24-hour Urine test, Saliva swab, Dexamethasone test
Sites
1 site in 1 country
- CHU de NimesNîmes, France